Mineralys Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-241.07Mn |
Net Profit Margins | -Inf% |
Mineralys Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Mineralys Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Mineralys Therapeutics, Inc. Common Stock’s net profit fell -457.08% since last year same period to $-241.07Mn in the Q2 2026. On a quarterly growth basis, Mineralys Therapeutics, Inc. Common Stock has generated -512.8% fall in its net profits since last 3-months.
Mineralys Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Mineralys Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.53 |
EPS Estimate Current Year | -0.53 |
Mineralys Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.53 - a 7.02% jump from last quarter’s estimates.
Mineralys Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.53.
Key Ratios
Earning Per Share (EPS) | -2.85 |
Mineralys Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -331.82% since last year same period to -2.85 in the Q2 2026. This indicates that the Mineralys Therapeutics, Inc. Common Stock has generated -331.82% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-06 | -0.44 | -0.47 | -6.82% |
2026-08-11 | -0.57 | -2.85 | -400% |
